EUVIMEDEUVIMED entdecken
Crossref

Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir–Rilpivirine

Sara Hockney iD, Dana Mueller, Alex Phillbrick, Jenna Berlet, Shannon Galvin

AIDS Research and Human Retroviruses · 01.07.2026 · 42 (6-7) · 227-229

DOI: 10.1177/08892229261449867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, online erschienen am 05.05.2026. Verfasst von Sara Hockney und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Anti-HIV Agents, Rilpivirine. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-acting injectable cabotegravir–rilpivirine (LA CAB/RPV) is an antiretroviral option for virologically suppressed people with HIV, but real-world discontinuation and failure patterns remain incompletely described. We retrospectively reviewed 201 adults who received LA CAB/RPV at a large academic infectious diseases clinic (January 2022–April 2025). Median time on therapy was 380 days (IQR 206–729). At the end of follow-up, 160 (80%) remained on LA CAB/RPV and 30 (15%) discontinued, most commonly due to insurance barriers ( n = 8, 27%); adherence issues and patient preference each accounted for 23% ( n = 7). Virologic failure occurred in 4 patients (2%) and was often accompanied by emergent or pre-existing non-nucleoside reverse transcriptase inhibitor and/or integrase strand transfer inhibitor resistance mutations; all patients achieved resuppression after switching back to oral ART. LA CAB/RPV was generally well tolerated, but system-level access and care-continuity barriers were major drivers of discontinuation, underscoring the importance of robust support systems and resistance-informed patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPyridonesAnti-HIV AgentsRilpivirineHumansRetrospective StudiesFemaleDiketopiperazinesMaleAdultMiddle AgedTreatment FailureViral LoadHIV-1Drug Resistance, Viral

Stichwörter der Autor:innen

HIVHIV treatmentantiretroviral therapycabotegravir–rilpivirinelong-acting antiretroviral therapyquality improvement

Substanzen

cabotegravirPyridonesAnti-HIV AgentsDiketopiperazinesRilpivirine

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Southwest Infectious Disease and Internal Medicine, Palos Heights, Illinois, USA.

ORCID-Profile: Sara Hockney

Zitieren

APA

Hockney, S., Mueller, D., Phillbrick, A., Berlet, J., & Galvin, S. (2026). Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir–Rilpivirine. AIDS Research and Human Retroviruses, 42(6-7), 227-229. https://doi.org/10.1177/08892229261449867

Vancouver

Hockney S, Mueller D, Phillbrick A, Berlet J, Galvin S. Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir–Rilpivirine. AIDS Research and Human Retroviruses. 2026;42(6-7):227-229. doi:10.1177/08892229261449867

BibTeX
@article{Hockney2026,
  author = {Hockney, Sara and Mueller, Dana and Phillbrick, Alex and Berlet, Jenna and Galvin, Shannon},
  title = {Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir–Rilpivirine},
  journal = {AIDS Research and Human Retroviruses},
  year = {2026},
  volume = {42},
  number = {6-7},
  pages = {227--229},
  doi = {10.1177/08892229261449867}
}
Kostenlos starten →